PURPOSE: The randomized, multicenter, phase III protocol C-07 compared the efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in stage II or III colon cancer. Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments. PATIENTS AND METHODS: Neurotoxicity was recorded for all patients using standard adverse event reporting. Patients at select institutions completed a neurotoxicity questionnaire through 18 months of follow-up. RESULTS: A total of 2,492 patients enrolled onto C-07 and 400 patients enrolled onto the patient-reported substudy. Mean patient-reported neurotoxicity was higher with oxaliplatin throughout the 18 months of study (P < .0001). During therapy, patients receiving oxaliplatin experienced significantly more hand/foot toxicity (eg, "quite a bit" of cold-induced hand/foot pain 26% FLOX v 2.6% FULV) and overall weakness (eg, moderate weakness in 27.4% FLOX v 16.2% FULV). At 18 months, hand neuropathy had diminished, but patients who received oxaliplatin experienced continued foot discomfort (eg, moderate foot numbness and tingling for 22.1% FLOX v 4.6% FULV). Observer-reported neurotoxicity was low grade and primarily neurosensory rather than neuromotor. Sixty-eight percent in the FLOX group v 8% in the FULV group had neurotoxicity at their first on-treatment assessment. Time to resolution was significantly longer for those receiving oxaliplatin, and continued beyond 2 years for more than 10% in the oxaliplatin group. CONCLUSION:Oxaliplatin causes significant neurotoxicity. It is experienced primarily in the hands during therapy and in the feet during follow-up. In a minority of patients the neurotoxicity is long lasting.
RCT Entities:
PURPOSE: The randomized, multicenter, phase III protocol C-07 compared the efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in stage II or III colon cancer. Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments. PATIENTS AND METHODS: Neurotoxicity was recorded for all patients using standard adverse event reporting. Patients at select institutions completed a neurotoxicity questionnaire through 18 months of follow-up. RESULTS: A total of 2,492 patients enrolled onto C-07 and 400 patients enrolled onto the patient-reported substudy. Mean patient-reported neurotoxicity was higher with oxaliplatin throughout the 18 months of study (P < .0001). During therapy, patients receiving oxaliplatin experienced significantly more hand/foot toxicity (eg, "quite a bit" of cold-induced hand/foot pain 26% FLOX v 2.6% FULV) and overall weakness (eg, moderate weakness in 27.4% FLOX v 16.2% FULV). At 18 months, hand neuropathy had diminished, but patients who received oxaliplatin experienced continued foot discomfort (eg, moderate foot numbness and tingling for 22.1% FLOX v 4.6% FULV). Observer-reported neurotoxicity was low grade and primarily neurosensory rather than neuromotor. Sixty-eight percent in the FLOX group v 8% in the FULV group had neurotoxicity at their first on-treatment assessment. Time to resolution was significantly longer for those receiving oxaliplatin, and continued beyond 2 years for more than 10% in the oxaliplatin group. CONCLUSION:Oxaliplatin causes significant neurotoxicity. It is experienced primarily in the hands during therapy and in the feet during follow-up. In a minority of patients the neurotoxicity is long lasting.
Authors: Jacobien M Kieffer; Tjeerd J Postma; Lonneke van de Poll-Franse; Floortje Mols; Jan J Heimans; Guido Cavaletti; Neil K Aaronson Journal: Qual Life Res Date: 2017-06-20 Impact factor: 4.147
Authors: Sina Vatandoust; Rohit Joshi; Kenneth B Pittman; Adrian Esterman; Vy Broadbridge; Jacqueline Adams; Nimit Singhal; Susan Yeend; Timothy Jay Price Journal: Support Care Cancer Date: 2014-02 Impact factor: 3.603
Authors: Barbara K Bennett; Susanna B Park; Cindy S-Y Lin; Michael L Friedlander; Matthew C Kiernan; David Goldstein Journal: Support Care Cancer Date: 2012-03-17 Impact factor: 3.603
Authors: Pauline A J Vissers; Floortje Mols; Melissa S Y Thong; Frans Pouwer; Gerard Vreugdenhil; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2015-02-03 Impact factor: 4.442
Authors: Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544